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Summary p53 and the murine double minute 2 (MDM2) oncoprotein expression was evaluated in paraffin-embedded tissue from 61 patients
with central nervous system gliomas (53 astrocytomas and eight oligodendrogliomas) and related to proliferation-associated markers [i.e.
proliferating cell nuclear antigen (PCNA), Ki-67 and nuclear organizer regions (NORs)] and epidermal growth factor receptor (EGFR). We
used the monoclonal antibodies PC-10, MIB-1, DO-1, 1Bi 0 and EGFR 113 and the colloid silver nitrate (AgNOR) technique. MDM2 and p53
were co-expressed in 28% of cases. A p53-positive/MDM2-negative phenotype was observed in 15% and a p53-negative/MDM2-positive
phenotype in 20% of cases. There was a positive correlation of p53 and MDM2 expression with grade and proliferation indices. Univariate
analysis in the group of diffuse astrocytomas showed that older age, high histological grade, high PCNA labelling index (LI) and high AgNOR
score were associated with reduced overall survival (P< 0.05). p53 LI, Ki-67 LI, AgNOR score, tumour location and grade influenced disease-
free survival (P < 0.05), whereas the only parameters affecting post-relapse survival were histological grade and Ki-67 LI (P< 0.1).
Multivariate analysis revealed that age, radiotherapy, PCNA LI and p53 LI were the independent predictors of overall survival. p53 LI, Ki-67
LI, MDM2 LI, EGFR LI, grade and type of therapy were independent predictors of disease-free survival, and grade was the only independent
predictor of post-relapse survival. Our results indicate that p53 LI and MDM2 LI, EGFR expression as well as proliferation markers (PCNA and
Ki-67) are useful indicators of overall and disease-free survival in diffuse astrocytoma patients.
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Central nervous system (CNS) gliomas range in clinical behaviour
and histological appearance from indolent well-differentiated
lesions to highly anaplastic, rapidly growing neoplasms. A cardinal
property ofalmost all types ofgliomas is a propensity to recur and
undergo anaplastic change (Russel and Rubinstein, 1989). A major
stimulus to the study of cell proliferation in gliomas has been the
widely held belief that quantification of this fundamental process
will be of value in the objective categorization of these tumours.
However, while cell kinetic information is an important aspect of
the biology of gliomas, it has become clear that neoplastic evolu-
tion towards glioblastoma is a multistep process that involves
deregulation of several genes related to both cellular proliferation
and differentiation. The molecular determinants ofglioma progres-
sion are still under investigation, with considerable attention
directed towards the tumour-suppressor gene p53. On the basis of
findings from molecular genetic analysis, Bigner and Vogelstein
(1990) have proposed the following model for malignant progres-
sion of gliomas: losses of chromosomes 17p (carrying p53 gene),
13 or 22 occur in low-grade gliomas and loss of chromosome 10
represents a critical step in transition from grade 3 to grade 4
gliomas of the astrocytic type, while abnormalities of 9p and
amplification of the epidermal growth factor receptor (EGFR)
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stimulate furtherprogression. Recently, theMDM2 gene was found
to be amplified and overexpressed in a proportion ofglioblastomas
and anaplastic astrocytomas, representing the second most
frequently amplified gene after the EGFR gene in these tumour
types (Reifenberger et al, 1993).
The aim ofthis study was to investigate the clinical significance
ofp53 and MDM2 oncoprotein expression in gliomas, as related to
established prognostic factors, proliferation markers - prolifer-
ating cell nuclear antigen (PCNA), Ki-67 and nucleolar organizer
regions (AgNORs) - and EGFR expression.
MATERIALS AND METHODS
Sixty-one patients were operated on for CNS gliomas at
Asklepeion Hospital, Voula, Athens, between 1985 and 1994. In
all cases, the diagnoses were peer reviewed by two experienced
pathologists. Histopathological assessment and grading were
based on the principles laid down in the new World Health
Organization Classification (Kleihues et al, 1993). Our cases fell
into two groups: astrocytoma and oligodendroglioma. The distrib-
ution of patients into grade and histological type categories is
shown in Table 1. As pilocytic astrocytomas and oligodendro-
gliomas differ substantially from diffuse astrocytomas in terms of
genetic evolution and clinical behaviour and their number in our
study was small, survival analysis was restricted to the group of
diffuse astrocytomas (51 cases).
There were 30 men and 21 women with a mean age of 55.4
years (range 31-79 years). The follow-up period lasted 1-50
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Table 1 PCNA LI, Ki-67 LI and AgNOR score for each histological type and grade
Grade No. of PCNA LI (%) Ki-67 LI (%) AgNOR score
cases Mean (s.d.) Mean (s.d.) Mean (s.d.)
Astrocytoma 1 2 7.55 (10.53) 0.25 (0.35) 2.27 (0.21)
2 7 18.86 (27.02) 10.65 (14) 2.18 (0.78)
3 7 32 (24.25) 6.29 (6.6) 2.64 (0.81)
4 37 38 (25.97) 15.80 (15) 3.13 (0.65)
Total 53 33.53 (26.84) 13.28 (15.09) 2.91 (0.72)
Oligodendroglioma 2 8 5.25 (4.83) 2.08 (3.16) 2.03 (0.5)
Table 2 Characteristics of antibodies used in this study
Antibody Specificity Dilution Incubation Source
time (h)
PC-10 PCNA 1:150 18 Dakopatts
MIB-1 Ki-67 Prediluted 1 YLEM
DO-1 P53 1:80 1 Oncogene
Science
1BlO MDM2 1:75 18 Novocastra
EGFR 113 EGFR 1:20 18 YLEM
months (mean 13.5 months). By the time this study was under-
taken, 46 patients had died after a mean survival of 12.4 months
(1-50 months), while five patients were alive after a mean follow-
up of22.6 months (range 9-38 months). All patients who died had
clear clinical evidence ofuncontrolled tumour at the time ofdeath.
Treatment consisted of curative surgery in nine patients, radio-
therapy in five patients and a combination of surgery and radio-
therapy in 33 patients. Seventeen patients relapsed after a mean
period of9.6 months (range 2-41 months).
The specimens had all been taken before radiotherapy was
given, fixed immediately after removal in 10% formalin and
processed toparaffin blocks. Only cases for which there was tissue
adequate for grading and immunohistochemistry were included in
this study. Representative serial sections were cut at 3-4 rm,
mounted on Vectabond-treated slides and allowed to dry at 37°C
overnight.
Immunohistochemistry and histochemistry
All cases were stained immunohistochemically for PCNA, Ki-67
antigen, p53 protein and MDM2 protein, and all but one case
were stained for EGFR, using the standard three-step strepta-
vidin-biotin technique. The source, dilution and incubation time
for each antibody are shown in Table 2. iB1O is an IgM-class
murine antibody raised against a recombinant part of the MDM2
protein that corresponds to a site on the carboxy-terminal portion
ofthe MDM2 molecule. EGFR 113 is a new monoclonal antibody
which detects the external domain ofEGFR molecule on paraffin-
embedded material.
For Ki-67 antigen and MDM2 protein, the high-temperature
antigen-unmasking technique was used as described by Norton et
al (1994). For EGFR, the same antigen-retrieval technique was
performed but the incubation time in the pressure cooker had to be
increased to 10 min. Before DO-1 application, slides were incu-
bated at 90°C for 15 min with Target Unmasking Fluid (TUF,
Kreatech), diluted 1:3 in distilled water. Following this procedure,
slides were left to cool in the unmasking solution for 15 min.
Known positive controls (normal tonsil for PC-10 and MIB-1, a
colorectal carcinoma for DO-1, a squamous cell carcinoma for
EGFR 113 and a sarcoma for lB10) were stained simultaneously
in each run. Negative controls consisting of sections in which the
primary antibody was substituted by non-immune mouse serum
were also stained.
Staining for all antibodies was assessed blind (i.e. without
knowing the histological diagnoses or the clinical data) by the
same observer. In each case, 1000 tumour cells were counted from
systematically randomized fields throughout the section. Endo-
thelial cells were not included in counts even though in some cases
they were labelled with PC-lO or MIB-1. The labelling index (LI)
for each antibody was calculated as the percentage of labelled
tumour cells out of the total number of tumour cells counted.
When regional heterogeneity of labelling was detected in the
tumour, areas containing the highest and lowest number of posi-
tive cells were selected, and the percentages were averaged to give
the LI. All clearly identifiable nuclear staining irrespective of
staining intensity was recorded as positive for PCNA and Ki-67.
For p53, a minimum of0.1% stained nuclei was required before a
case was accepted as positive, as proposed by Pignatelli et al
(1992). For MDM2, the threshold of positivity was raised to 5%
according to Barbareschi et al (1995). Concerning EGFR, a case
was recorded as positive if it showed clear cytoplasmic and/or
membrane staining beyond background.
Staining and AgNOR enumeration were performed as previ-
ously described (Korkolopoulou et al, 1994).
Statistical analysis
The prognostic effect of various parameters with natural categor-
ization, i.e. sex, histological grade (II, III, IV), p53 (positive vs
negative), MDM2 (positive vs negative), EGFR (positive vs nega-
tive), extent of surgery (total, subtotal, partial, biopsy), radio-
therapy (yes/no) and location (frontal lobe, temporal lobe, parietal
lobe, occipital lobe, two lobes affected, cerebellum) was assessed
by plotting Kaplan-Meier curves and comparing groups using the
log-rank test (Cox, 1972). The continuous variables, i.e. age,
PCNA LI, Ki-67 LI and AgNOR score were categorized on the
basis of the mean value; Ki-67 was also considered in the form of
< 5% vs .5% according to theresults ofaprevious study (Jaros et
al, 1992). Multivariate analysis was performed using the stepwise
Cox regression model to evaluate the predictive power of each
variable independently of the others. In order to avoid any 'data-
driven' categorization, age, PCNA LI, Ki-67 LI, AgNOR score,
MDM2 LI, p53 LI and EGFR LI were entered in multivariate
analysis as continuous and categorical variables. Statistical
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Figure 1 PCNA immunostaining in (A) a grade 11 astrocytoma showing a single positive cell (arrow) (bar = 50gm) and (B) a grade IlIl astrocytoma showing
many positive cells (bar = 50 ,um)
A B
Figure 2 Ki-67 (MIB-1) immunostaining in (A) a grade 11 astrocytoma showing scattered positive cells (bar = 50 gm) and (B) a grade IV astrocytoma showing
many positive cells (bar = 100gm)
analysis was performed using the SPSS for Windows software
(SPSS, Chicago, IL, USA).
The relationships between various parameters were evaluated
statistically using chi-square Wilcoxon test, one way ANOVA,
Spearman's and Pearson's correlation coefficients.
RESULTS
Immunohistochemistry and histochemistry
PCNA and Ki-67 immunoreactivity was evident as nuclear
staining, granular ordiffuse, with nucleolar accentuation for Ki-67
(Figures 1 and 2). The mean (± s.d.) values ofPCNA and Ki-67 LI
for each histological type and grade are shown in Table 1. The
adjacent nervous tissue was always negative. ANOVA indicated a
statistically significant difference in PCNA LI and Ki-67 LI
between astrocytomas andoligodendrogliomas (P = 0.001 and P =
0.027 respectively), astrocytomas tending to display higher LUs.
An increase ofPCNA LI with increasing grade ofmalignancy was
also noted (P = 0.002). The relationship between Ki-67 LI and
grade was less clear and ofborderline significance (P = 0.057).
With the AgNOR method, a variable number ofclearly defined
'dots' or 'blebs' were identified in all nuclei (Figure 3). The mean
AgNOR scores for each histological type and grade are given in
Table 1. It can be observed that the mean number ofAgNORs per
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Figure 3 AgNOR staining in (A) a grade 11 astrocytoma; neoplastic cells contain one to two AgNORs per nucleus (bar = 25 gm) and (B) a grade IV astrocytoma;
neoplastic cells contain numerous AgNORs per nucleus (bar = 25 jIm)
A B
Figure 4 p53 immunostaining in (A) a grade IV astrocytoma showing a few positive cells (bar = 50 ,um) and (B) a grade IV astrocytoma showing numerous
positive cells (bar = 50gm)
nucleus clearly correlates with histological type and malignancy
grade, in the sense that astrocytomas and high-grade tumours tend
to possess more AgNORs (P < 0.001).
p53 and MDM2 labelling were restricted to tumour cell nuclei.
Oligodendrogliomas were negative forp53, and pilocytic (grade I)
astrocytomas were negative for both p53 and MDM2. A fine gran-
ular staining was characteristic of lB10 antibody whereas DO-1
staining was usually stronger and had either granular or diffuse
quality (Figures 4 and 5). Normal nervous tissue was negative as
were endothelial cells, even in cases with marked endothelial
proliferation. A striking heterogeneity in labelling with both anti-
bodies was observed in some (20-25%) cases. Three types of
immunopositivity were observed: (1) simultaneous MDM2 and
p53 expression in 17 cases (28%), seven of which had p53 LIs
greater than 10% -close examination ofserial sections in all seven
cases revealed thatp53 and MDM2 were co-expressed in apropor-
tion of neoplastic nuclei; (2) p53 expression without MDM2 in
nine cases (15%); and (3) MDM2 expression without p53 in 12
cases (20%). LIs for both proteins varied within each grade and
histological type ranging from 0.1% to 55% for p53 and from 5%
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Figure 5 MDM2 immunostaining in a grade IlIl astrocytoma showing many poc
A B
Figure 6 EGFR immunostaining in (A) a grade 11 astrocytoma showing few positive cells (bar = 50gm) and (B) a grade IV astrocytoma; almost all neoplastic
cells are positive (bar = 50 ,um). Note that vessel (V) is negative
Table 3 p53, MDM2 and EGFR immunostaining in each histological type and grade
Grade No. of cases p53 immunostaining MDM2 immunostaining EGFR immunostaining
Negative Mean p53 Li (s.d.) Negative Mean MDM2 LI (s.d.) Negative Mean EGFR LI (s.d.)
Astrocytoma 1 2 2 - 2 - 2 -
2 7 5 4 (1.41) 5 11 (1.41) 5 10.25 (13.8)
3 7 5 26 (12.72) 4 6 (1.73) 4 20 (18)
4 37 15 10.7 (17.06) 15 26.05 (16.92) 20 27.68 (33.03)
Total 53 27 11.36 (16.89) 26 22.71 (16.18) 31 25.05 (31.03)
Oligodendroglioma 2 8 8 - 6 40 (49.5) 7 20
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Table 4 Correlation coefficients between PCNA LI, Ki-67 LI, AgNOR score, p53 LI, MDM2 LI and EGFR LI
p53 LI PCNA LI Ki-67 LI AgNOR score MDM2 LI
PCNA LI 0.41 (P = 0.001)
Ki-67 LI 0.49 (P< 0.001) 0.55 (P< 0.001)
AgNOR score 0.33 (P= 0.009) 0.49 (P< 0.0001) 0.37 (P= 0.010)
MDM2 LI 0.30 (P= 0.002) 0.43 (P= 0.001) 0.43 (P = 0.001) 0.31 (P= 0.018)
EGFR LI 0.20 (P= 0.135) 0.25 (P= 0.061) 0.17 (P= 0.195) 0.16 (P= 0.25) 0.04 (P= 0.749)
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Figure 7 Overall survival of diffuse astrocytoma patients in relation to PCNA immunostaining (A), Ki-67 (MIB-1) immunostaining (B), AgNOR staining (C), p53
immunostaining (D), MDM2 immunostaining (E) and EGFR immunostaining (F)
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to 75% forMDM2 (Table 3). The rate ofpositivity was significantly
associated with the malignancy grade in that more positive cases
for p53 and MDM2 were seen in higher grades (chi-square test,
P < 0.01 for p53 and P < 0.05 for MDM2). p53 LI did not correlate
with grade (P > 0.05) but MDM2 LI did (P = 0.01). Astrocytomas
expressed MDM2 more often than oligodendrogliomas but the
difference was not statistically significant (P > 0.05).
EGFR staining was seen in 23 cases (38%). Labelling was
restricted mainly to cytoplasm and in some cases also to cell
membrane (Figure 6). Normal nervous tissue and endothelial cells
did not stain with the anti-EGFR antibody. In some tumours, the
distribution ofstaining was uniform but in others a patchy distrib-
ution ofpositive cells was seen. As with p53 and MDM2, none of
the grade I tumours were labelled for EGFR, and the proportion of
positive tumours increased with tumour grade (chi-square test,
P < 0.1). Astrocytomas were also more often positive for EGFR
than oligodendrogliomas (42% vs 13%; chi-square test, P > 0.05).
EGFR LI did not correlate with grade (P > 0.05).
Relationships among PCNA, Ki-67, AgNORs, p53,
MDM2 and EGFR
The correlation coefficients among PCNA LI, Ki-67 LI, AgNOR
score, p53 LI, MDM2 LI and EGFR LI are shown in Table 4. The
relationships among the various markers are best described by the
following simple linear regression equations: PCNA LI = (0.867 x
Ki-67 LI) + (7.8p3 x AgNOR score); p53 LI = 0.018 x PCNA LI;
Ki-67 LI = 0.341 x PCNA LI; AgNOR score = 2.408 + 0.014 x
PCNA LI; MDM2 LI = 4.265 x AgNOR score; and EGFR LI =
0.250 x PCNA LI.
Survival analysis
In univariate analysis of astrocytomas, the parameters showing a
significant correlation with overall survival were PCNA LI (P =
0.0025), AgNOR score (P = 0.015), tumour grade (P = 0.0137)
and the age of the patient at diagnosis (P = 0.0159). p53 LI and
MDM2 LI were ofborderline significance (P = 0.06 and P = 0.10
respectively), whereas EGFR positivity was not significant (P =
0.64). The Kaplan-Meier curves for PCNA LI, Ki-67 LI, AgNOR
score, p53 LI, MDM2 LI and EGFR LI are depicted in Figure 7.
Accordingly, the parameters influencing disease-free survival
were p53 LI (P = 0.0035), AgNOR score (P = 0.0046), tumour
location (P = 0.03), Ki-67 LI (P = 0.043) and grade (P = 0.046).
Histological grade and Ki-67 LI were the only parameters of
borderline significance influencing post-relapse survival (P = 0.07
and P = 0.09 respectively). We also examined survival in grade IV
astrocytomas in relation to the combined p53/MDM2 expression.
Patients with tumours displaying the p53-positive/MDM2-positive
phenotype had the poorest prognosis (P = 0.06).
In multivariate analysis, the forward and backward selection
strategy disclosed that factors predicting overall survival indepen-
dently were PCNA LI, p53 LI, radiotherapy and age. Low PCNA
LI and p53 LI, radiotherapy and young age were favourable prog-
nostic indicators (Table 5). Multivariate analysis for the group of
patients who relapsed showed that p53 LI, Ki-67 LI, MDM2 LI,
EGFR LI, grade and the type of therapy were the statistically
significant independent prognostic parameters (Table 5). It is note-
worthy that MDM2 expression is associated with longer disease-
free survival. When survival from the first relapse was considered,
statistical analysis resulted in one parameter, namely histological
grade (Table 5).
DISCUSSION
The p53 gene, located on chromosome 17p, encodes a 53-kDa
nuclear phosphoprotein which can bind to DNA and act as a tran-
scription factor. Normalp53 is believed to function as an inhibitor
of cell replication when DNA damage is sustained. It is generally
undetectable by standard immunohistochemistry because ofits low
cellular levels and a very short half-life (Finlay, 1989). Mutations
of the gene occurring within the coding region usually lead to the
production of a non-functional protein which, being much more
stable than the wild protein, accumulates in the nucleus reaching
Table 5 Cox's proportional hazard estimation of overall, disease-free and post-relapse survival
Covariate Coefficient Standard error Pvalue Relative risk Relative risk
confidence interval
Overall survival
Age 0.0556 0.0169 0.0010 1.0572 1.0227-1.0928
Radiotherapy -0.4745 0.1810 0.0088 0.622 0.4363-0.8872
p53 LI 0.0339 0.0148 0.0217 1.0345 1.0050-1.0648
PCNA LI 0.0183 0.0064 0.0041 1.0185 1.0058-1.0313
Disease-free survival
Radiotherapy -2.1716 0.8785 0.0134 0.1140 0.0204-0.6378
p53 LI 0.0882 0.0296 0.0029 1.0922 1.0307-1.1574
Ki-67 LI 0.2336 0.1039 0.0246 1.2632 1.0304-1.5485
MDM2 LI -0.1183 0.0456 0.0096 0.8885 0.8124-0.9716
EGFR LI 0.2698 0.1198 0.0243 1.3097 1.0356-1.6563
Surgery 0.0262
Partial excision
Subtotal excision 2.4658 0.9575 0.01 0.0849 0.0130-0.5548
Total excision 0.8491 0.4525 0.0606 2.3376 0.9630-5.6743
Histological grade 1.4916 0.7359 0.0427 4.4443 1.0506-18.8008
Post-relapse survival
Histological grade 1.8719 0.8147 0.0216 6.5005 1.3166-32.0943
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the threshold ofimmunohistochemical detection (Iggo et al, 1990).
On the other hand, in addition to being of wild type, p53 may not
be detectable immunohistochemically because the gene is deleted
or a stop codon has formed (Maestro et al, 1992). Moreover, p53
protein can be stabilized and therefore detected immunohisto-
chemically by binding to various proteins, such as large T antigen,
70-kDa heat-shock protein (Lane, 1992) and MDM2 protein. The
last is a 90-kDa protein that has the ability to form complexes with
both wild and mutant types ofp53 and acts as a specific p53 antag-
onist by concealing its activation domain (Momand et al, 1992).
An autoregulatory feedback loop seems to exist between MDM2
and p53 in the sense that the MDM2 gene is inducible by wild p53
protein whereas MDM2 protein regulates p53 protein at the level
of its activity. This loop maintains a critical MDM2-p53 ratio
within the cell (Meltzer, 1994). In vivo, the MDM2 gene is
commonly amplified in soft tissue sarcomas (Cordon-Cardo et al,
1994). The functional link between p53 and MDM2, however, may
not be as clear as is believed, at least in some cellular systems, and
MDM2 may have other functions unrelated to those resulting from
interactions with p53 (Xiao et al, 1995).
Molecular studies of human gliomas have demonstrated that
approximately 25-45% of them harbour p53 gene mutations
(mainly missense mutations) (Louis, 1994). There is a plethora of
recent papers on p53 immunohistochemical demonstration in
gliomas (Barbareschi et al, 1992; Haapasalo et al, 1993; Louis et
al, 1993; Newcomb et al, 1993; Soini et al, 1994; Kyritsis et al,
1996) in which positive staining was found in 40-65% of cases, a
figure similar to that quoted in the present study. The discrepancy
between p53 mutations and p53 immunopositivity has been attrib-
uted mainly to wild p53 protein accumulation (Rubio et al, 1993),
although mutations outside the conserved region cannot be
excluded (Kyritsis et al, 1996). Cytoplasmic staining as reported
by other authors (Barbareschi et al, 1992; Soini et al, 1994) was
not observed in our series. p53 positivity was restricted to astro-
cytic cell lineage, in keeping with the very low frequency of p53
mutations in non-astrocytic gliomas (Ohgaki et al, 1991). p53
positivity tended to be associated with a high-grade histology in
accordance with previous studies (Barbareschi et al, 1992; Soini et
al, 1994). Similarly, MDM2 protein was expressed in 48% ofcases
and was significantly associated with a high-grade phenotype. The
much higher percentage of gliomas expressing MDM2 than
gliomas with MDM2 gene amplification (8-10%) reported by
Reifenberger et al (1993) probably reflects increased transcription
of the gene or post-translational stabilization of MDM2 protein.
The majority of cases expressing p53 also overexpressed MDM2,
implying that either MDM2 overexpression is responsible for the
stabilization of wild p53 protein or there is an underlying p53
mutation possessing MDM2 transactivation abilities. The fact,
however, that a substantial number of cases express MDM2 but
not p53 suggests ap53-independent mechanism ofMDM2 overex-
pression. Finally, the p53-positive/MDM2-negative phenotype is
indicative of a p53 mutation that is unable to activate the MDM2
gene. The relationship between p53 and proliferation indices is in
agreement with data showing that p53 mRNA levels increase in
association with cell proliferation (Reich and Levine, 1984) and
could be linked to the effect that p53 exerts on the PCNA gene
(Mercer et al, 1991). Interestingly, a relationship was also estab-
lished between MDM2 and proliferation. A plausible explanation
is that increased MDM2 expression inactivates p53, blocking its
antiproliferative function. There is a limited number of studies
addressing the possible association of p53 immunopositivity with
poor prognosis (Jaros et al, 1992; Soini et al, 1994), the findings of
which agree with ours, although unpublished data reported by
Louis et al (1994) have failed to confirm this association. Taking
into account that p53 mutations are commoner in youngerpatients
and in astrocytomas progressing stepwise to glioblastomas (van
Meyel et al, 1994), it is tempting to hypothesize that patients
whose tumours carry p53 mutations may survive longer. Although
this assumption is seemingly at discrepancy with our results, one
must bear in mind that p53 immunopositivity in gliomas is in
many cases due to wild type protein accumulation and that the
stabilization of the wild p53 protein - and not thep53 gene status
per se - may in itself facilitate glioma progression (Rubio et al,
1993). In this perspective, evaluation ofthe combined MDM2/p53
protein phenotype could have prognostic relevance and may be
more informative than evaluation of the p53 or MDM2 protein
alone, as suggested by our findings in grade IV astrocytomas.
The EGFR gene is found on chromosome 7. It encodes a 170-
kDa transmembrane glycoprotein with an extracellular ligand-
binding domain, a transmembrane region and an intracellular
portion with tyrosine kinase activity (Hunter, 1984). Amplification
and rearrangement of the EGFR gene with overexpression of its
product have been reported in 40-50% ofglioblastoma multiforme
and in a minority of anaplastic astrocytomas (Liberman et al,
1984; Reifenberger et al, 1989, 1993; Diedrich et al, 1995). Our
results concur with these findings. The association between p53 LI
and EGFR LI, as well as the simultaneous expression ofthese two
molecules in a significant proportion (23%) of our cases, suggests
that p53 and EGFR may be involved in early stages of glial
tumorigenesis, as hypothesized by Jaros et al (1992) and Rasheed
et al (1994), and that this expression may be associated with
progression to more anaplastic forms ofgliomas. The cytoplasmic
distribution of EGFR that we and others (Jaros et al, 1992) have
observed may be explained by rapid internalization of the
EGF-EGFR complex orby cytoplasmic binding ofEGFR to TGF-
a (Jaros et al, 1992). In univariate analysis, EGFR expression
failed to emerge as a significant predictorofsurvival, in contrast to
the findings of Diedrich et al (1995) and Zhu et al (1996). The
latter, however, studied only irradiated tumours.
Various studies performed in this and other laboratories have
shown an overall positive correlation between histological grade
of gliomas and cellular proliferation parameters, including Ki-67
(or MIB-1) LI (Burger et al, 1986; Zuber et al, 1988; Schroder,
1991; Karamitopoulou et al, 1994; Sallinen et al, 1994), PCNA LI
(Allegranza et al, 1991; Louis et al, 1991; Karamitopoulou et al,
1993; Korkolopoulou et al, 1993) and AgNOR number (Maier et
al, 1990; Plate et al, 1991; Korkolopoulou et al 1993), lending
support to the findings of the present study. However, there is
significant overlap in the expression of proliferation indices
among various grades, so that none of them can be used as a reli-
able grading tool. In a previous study (Korkolopoulou et al, 1994),
we found that PCNA LI has a significant impact on glioma
survival. The present study strengthens this finding, as well as the
prognostic significance of the other indices of cell proliferation
(i.e. Ki-67 LI and AgNOR score) (Kajiwara et al, 1990; Sallinen et
al, 1994). However, other authors have failed to substantiate the
prognostic effect of proliferation indices in gliomas (Zuber et al,
1988; Nicoll et al, 1991; Figge et al, 1992; Karkavelas et al, 1995).
The rather strong relationship between the three proliferation-
associated indices we have used is also in agreement with
previously reported findings (Korkolopoulou et al, 1993; Sallinen
et al, 1994).
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To our knowledge, our study is the first to correlate proliferation
data, p53 and MDM2 oncoprotein expression and EGFR expres-
sion with survival in gliomas. Multivariate analysis demonstrated
that overall survival in astrocytomas can be predicted by the age of
the patient, PCNA LI, p53 LI and radiotherapy. The information
conveyed by these parameters is superior to that yielded by
conventional histopathological grading. This is in agreement with
the findings of previous studies (Korkolopoulou et al, 1994;
Vigliani et al, 1994). The failure of other authors to establish an
independent prognostic significance for PCNA LI may be because
of different staining protocols and scoring methods (Theunissen
and Blaauw, 1993; Sallinen et al, 1994). On the contrary, p53 LI
and MDM2 LI were the most statistically significant parameters in
predicting disease-free survival independently. However, MDM2
LI did not attain a statistical significance in univariate analysis
because its direct favourable prognostic effect was masked by its
relationship with histological grade, p53 LI and proliferation
indices. Finally, histological grade was superior to the aforemen-
tioned parameters only in predicting post-recurrence survival.
In conclusion, this study establishes the prognostic value ofcell
proliferation indices (PCNA and Ki-67), oncoprotein expression
(p53 and MDM2) and EGFR in overall and disease-free survival
ofpatients with diffuse astrocytomas. More importantly, it demon-
strates that PCNA LI and p53 LI are more significant predictors of
overall survival than histological grade. The only other factors
with independent prognostic significance are the age ofthe patient
and the type of treatment. Should these observations be validated
by prospective studies, the above parameters could be incorpor-
ated into the routine evaluation of astrocytomas to improve the
prognostic accuracy ofthe current histopathological criteria.
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